about
Tracking a refined eIF4E-binding motif reveals Angel1 as a new partner of eIF4EPostnatal deamidation of 4E-BP2 in brain enhances its association with raptor and alters kinetics of excitatory synaptic transmissionControl of Paip1-eukayrotic translation initiation factor 3 interaction by amino acids through S6 kinaseTranslational homeostasis via the mRNA cap-binding protein, eIF4EEpigenetic activation of a subset of mRNAs by eIF4E explains its effects on cell proliferationThe helicase protein DHX29 promotes translation initiation, cell proliferation, and tumorigenesisVesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production.4E-BP restrains eIF4E phosphorylationEssential role for SphK1/S1P signaling to regulate hypoxia-inducible factor 2α expression and activity in cancer.Regulation of poly(A)-binding protein through PABP-interacting proteins.Poly(A)-binding protein-interacting protein 1 binds to eukaryotic translation initiation factor 3 to stimulate translation.Fibroblast growth factor 1 induced during myogenesis by a transcription-translation coupling mechanism.Control of cell survival and proliferation by mammalian eukaryotic initiation factor 4B.Repair of isoaspartate formation modulates the interaction of deamidated 4E-BP2 with mTORC1 in brain.Mitochondrial energetic and AKT status mediate metabolic effects and apoptosis of metformin in human leukemic cells.Imbalanced splicing in MAPK signaling sustains Ras-induced transformation.Pancreatic tumours escape from translational control through 4E-BP1 loss.p53-dependent translational control of senescence and transformation via 4E-BPs.Translational control of the innate immune response through IRF-7Differential Regulation of the Three Eukaryotic mRNA Translation Initiation Factor (eIF) 4Gs by the Proteasome[When translation arises from its TORpor].eIF4A inhibition circumvents uncontrolled DNA replication mediated by 4E-BP1 loss in pancreatic cancerThe GLP1R Agonist Liraglutide Reduces Hyperglucagonemia Induced by the SGLT2 Inhibitor Dapagliflozin via Somatostatin Release
P50
Q24297096-D6599AD1-73A7-4FC1-995A-0EE2564761D0Q24304928-59529495-6725-4AD7-A1C9-2096BA50A759Q24317685-E21BB97D-A6DD-464D-90FD-3AB248D0E602Q24320659-D2B6011D-497B-41F4-AB9F-F9F2710178D6Q33274677-E58BB6FC-FD1A-4EEA-A192-12442BA4FC69Q33564231-A4F5A6D3-E41C-414B-83F7-D954542602F3Q33667768-BEFE159E-8D4B-44D1-B4D6-D1AA2420F1BFQ36477529-65B4E81F-72C1-4B24-B7EC-6005EC2D902FQ36748690-AE70F9DC-57FE-42E3-AC6D-31A2726DD473Q36768223-6C43141B-ACF9-4FD4-B2A5-FB724E9B8115Q36949719-58B83701-EF32-484E-B43A-F018253C7FA9Q37384774-2B2FBDAF-70C6-4882-8DAC-B78D7A0A63D6Q39414084-DDC975E5-48BE-42A6-A89B-E99561BDD369Q41048721-E8C0E93B-D3C5-44AA-A99D-0339F730BA7BQ42436880-41334EFE-19EA-481C-9A69-E5D797D5809EQ53227021-52F6DA8E-43C8-4075-8770-42584123BA3BQ53255717-172925B3-A009-4EAB-8926-39DB5DE153F2Q53305156-A267B33C-B2C2-42A3-9EAA-249C28B39EE5Q57203299-09B0EB18-9DB2-4904-A94E-ECA32DE63807Q64102093-8E22B80E-ED70-434C-BCF8-E2A26549FC11Q64969285-339834F0-62DA-410A-B4B8-D9F66D1A68ADQ91044608-A8AB4A9C-2C30-43C3-8D5D-BDAF8AD47998Q92477544-C065C482-B819-4AD4-8C33-E62AF8E3F4C8
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Yvan Martineau
@ast
Yvan Martineau
@en
Yvan Martineau
@es
Yvan Martineau
@nl
Yvan Martineau
@sl
type
label
Yvan Martineau
@ast
Yvan Martineau
@en
Yvan Martineau
@es
Yvan Martineau
@nl
Yvan Martineau
@sl
prefLabel
Yvan Martineau
@ast
Yvan Martineau
@en
Yvan Martineau
@es
Yvan Martineau
@nl
Yvan Martineau
@sl
P106
P31
P496
0000-0002-0575-4085